We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $47.78, marking a -1.63% move from the previous day. This change lagged the S&P 500's 1.01% loss on the day. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.4%.
Shares of the company have depreciated by 10.21% over the course of the past month, underperforming the Medical sector's gain of 5.37%, and the S&P 500's gain of 0.32%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$1.1, marking a 14.73% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 million, showing a 733.26% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.9 per share and a revenue of $28.88 million, signifying shifts of +24.27% and +722.82%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.26% lower within the past month. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $47.78, marking a -1.63% move from the previous day. This change lagged the S&P 500's 1.01% loss on the day. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.4%.
Shares of the company have depreciated by 10.21% over the course of the past month, underperforming the Medical sector's gain of 5.37%, and the S&P 500's gain of 0.32%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$1.1, marking a 14.73% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 million, showing a 733.26% escalation compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.9 per share and a revenue of $28.88 million, signifying shifts of +24.27% and +722.82%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.26% lower within the past month. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.